BioSig to Host Conference Call on December 21, 2021
December 13 2021 - 8:30AM
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that it would host a conference call on
Tuesday, December 21, 2021, at 2 PM ET.
Conference Call DetailsDate: Tuesday, December
21, 2021Time: 2:00 PM Eastern Time (ET)Dial-in number for US
callers (toll-free): 877-407-8293Dial-in number for U.S. and
international callers (toll): +1 201-689-8349
To join the conference call online, please
click here: BioSig Webcast
A webcast replay will be available two hours after the event’s
conclusion and archived for six months.
The PURE EP (tm) is an FDA 510(k) cleared non-invasive
class II device that aims to drive procedural efficiency and
efficacy in cardiac electrophysiology. Clinical data acquired by
the PURE EP (tm) System in a multi-center study at Texas
Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo
Clinic Jacksonville, and Massachusetts General Hospital was
recently published in the Journal of Cardiovascular
Electrophysiology and is available electronically with open access
via the Wiley Online Library. Study results showed 93% consensus
across the blinded reviewers with a 75% overall improvement in
intracardiac signal quality and confidence in interpreting PURE EP
(tm) signals over conventional sources.
One in 18 Americans suffers from a cardiac arrhythmia. Atrial
fibrillation is the most common arrhythmia type, affecting over 33
million people worldwide, including over 6 million in the U.S. The
number of people suffering from atrial fibrillation is expected to
reach 8-12 million by 20501. According to the Centers for
Disease Control and Prevention (CDC), atrial fibrillation causes
more than 750,000 hospitalizations in the U.S. each year, resulting
in approximately $6 billion in healthcare spending annually2.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals. (www.biosig.com).
The Company’s first product, PURE EP (tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory. To date, 73 physicians have completed
over 1750 patient cases with the PURE EP (tm)
system. The Company is in a focused commercial launch of the PURE
EP (tm) System in the Northeast, Texas, and Florida.
The technology is regularly used in some of the country’s
highest-ranked hospitals, including St. David’s Medical Center in
Austin, TX, Mayo Clinic campuses in Florida, Minnesota, and
Arizona, and University of Pennsylvania in Philadelphia, PA.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Top 10 Things You should Know About Heart Rhythm; Scripps
Health.
2 Managing Atrial Fibrillation; Lisa Eramom MA, Medical
Economics Journal, February 25, 2019, Volume 96, Issue 4
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024